Does Creative Medical Technology Holdings Inc. (CELZ) offer a good opportunity for investors?

Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) stock jumped 10.44% on Tuesday to $0.51 against a previous-day closing price of $0.46. With 0.18 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.47 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.5199 whereas the lowest price it dropped to was $0.4600. The 52-week range on CELZ shows that it touched its highest point at $5.14 and its lowest point at $0.33 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 4.90.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CELZ was up-trending over the past week, with a rise of 9.86%, but this was up by 41.44% over a month. Three-month performance surged to 15.75% while six-month performance fell -23.79%. The stock lost -79.85% in the past year, while it has gained 33.80% so far this year. A look at the trailing 12-month EPS for CELZ yields -1.56 with Next year EPS estimates of -0.51. For the next quarter, that number is -0.13. This implies an EPS growth rate of 109.40% for this year and 16.40% for next year.

Float and Shares Shorts:

At present, 14.07 million CELZ shares are outstanding with a float of 13.72 million shares on hand for trading. On Dec 29, 2022, short shares totaled 0.16 million, which was 1.16% higher than short shares on Nov 29, 2022. In addition to Mr. Timothy Warbington as the firm’s Chairman, Pres & CEO, Mr. Donald Dickerson serves as its Sr. VP, CFO & Director.

Institutional Ownership:

Through their ownership of 9.12% of CELZ’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 3.53% of CELZ, in contrast to 1.72% held by mutual funds. Shares owned by individuals account for 0.66%. As the largest shareholder in CELZ with 1.83% of the stake, Citadel Securities LLC holds 257,866 shares worth 257,866. A second-largest stockholder of CELZ, Boothbay Fund Management LLC, holds 88,889 shares, controlling over 0.63% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in CELZ, holding 61,050 shares or 0.43% stake. With a 0.43% stake in CELZ, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 61,050 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.17% of CELZ stock, is the second-largest Mutual Fund holder. It holds 24,157 shares valued at 9204.0. Fidelity Series Total Market Inde holds 0.05% of the stake in CELZ, owning 7,244 shares worth 2760.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, CELZ reported revenue of $0.00 and operating income of -$1.79M. The EBITDA in the recently reported quarter was -$1.77M and diluted EPS was -$0.20.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CELZ since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CELZ analysts setting a high price target of $10.00 and a low target of $10.00, the average target price over the next 12 months is $10.00. Based on these targets, CELZ could surge 1860.78% to reach the target high and rise by 1860.78% to reach the target low. Reaching the average price target will result in a growth of 1860.78% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CELZ will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of -$0.61 being high and -$0.61 being low. For CELZ, this leads to a yearly average estimate of -$0.61. The surprise factor in the prior quarter was -$0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.13 and the low estimate is -$0.13. The average estimate for the next quarter is thus -$0.13.

Leave a Comment

Your email address will not be published. Required fields are marked *